Cornerstone Therapeutics, Inc. (CRTX) Misses Q3 EPS by 1c, Sales Fall Below Expectations

Cornerstone Therapeutics, Inc. (NASDAQ: CRTX) reported Q3 non-GAAP EPS of $0.13, $0.01 worse than the analyst estimate of $0.14. Revenue for the quarter came in at $25.18 million versus the consensus estimate of $28.39 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M